AbbVievs.Bristol Myers Squibb
ABBV vs BMY · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
AbbVie is about 3.7× larger than Bristol Myers Squibb by market cap; Bristol Myers Squibb trades at the lower P/E (19.6 vs 120.6).
Side by side
| ABBV | BMY | |
|---|---|---|
| Market cap | $438B | $117B |
| Price | $248.08 | $57.58 |
| Today | −0.7% | −0.6% |
| Return YTD | +8.6% | +6.7% |
| Return 1Y | +27.2% | +18.7% |
| P/E | 120.6 | 19.6 |
| P/S | 7.0 | 2.4 |
| P/B | 308.7 | 5.8 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
AbbVieABBV
Large biopharma with immunology (Skyrizi, Rinvoq), oncology and neuroscience.
Full ABBV profile →Bristol Myers SquibbBMY
American pharmaceutical group with strengths in oncology (Opdivo) and immunology, plus a neuroscience pipeline.
Full BMY profile →More comparisons in Big pharma
See where ABBV and BMY sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →